Research Article
Diagnostic and Prognostic Significance of Serum Biomarkers CA 125 and CA 19-9 in Ovarian Cancer
Issue:
Volume 10, Issue 1, March 2025
Pages:
1-6
Received:
21 December 2024
Accepted:
3 January 2025
Published:
21 January 2025
DOI:
10.11648/j.ijcocr.20251001.11
Downloads:
Views:
Abstract: Background: Ovarian cancer is a significant cause of gynecological cancer-related mortality, with early diagnosis being critical for better outcomes. Serum biomarkers CA 125 and CA 19-9 are widely studied for their diagnostic and prognostic significance in ovarian cancer. Methods: This cross-sectional study analyzed 80 ovarian cancer patients from January to December 2018 at BSMMU, Dhaka. Data included socio-demographic profiles, serum levels of CA 125 and CA 19-9 and their correlation with cancer stage and histological subtypes. Diagnostic performance metrics of CA 125 for advanced stages (III/IV) were also evaluated. Statistical analyses were performed using SPSS. Results: The mean serum CA 125 level was 350.54 ± 120.35 IU/mL, with 85% of cases showing elevated levels. CA 125 levels increased significantly with cancer stage (Stage I: 151 ± 50 IU/mL, Stage IV: 950 ± 305 IU/mL, *p* < 0.001). The mean serum CA 19-9 level was 90.42 ± 45.59 IU/mL, elevated in 40% of cases, with higher levels observed in mucinous subtypes. CA 125 demonstrated high sensitivity (82%) and specificity (75%) for detecting advanced stages. Conclusion: Serum CA 125 is a reliable biomarker for staging and diagnosing advanced ovarian cancer, with CA 19-9 providing additional insights into histological subtypes. These findings reinforce the clinical utility of these biomarkers in managing ovarian cancer.
Abstract: Background: Ovarian cancer is a significant cause of gynecological cancer-related mortality, with early diagnosis being critical for better outcomes. Serum biomarkers CA 125 and CA 19-9 are widely studied for their diagnostic and prognostic significance in ovarian cancer. Methods: This cross-sectional study analyzed 80 ovarian cancer patients from ...
Show More
Research Article
Impact of Preoperative Systemic Inflammation Score on Key Prognostic Risk Factors in Early Cervical Cancer
Issue:
Volume 10, Issue 1, March 2025
Pages:
7-13
Received:
23 December 2024
Accepted:
6 January 2025
Published:
23 January 2025
DOI:
10.11648/j.ijcocr.20251001.12
Downloads:
Views:
Abstract: Background: Cervical cancer is the fourth most common malignancy in women across the world. Treatment decisions for early cervical cancer are guided by prognostic risk factors including tumor size, LVSI, depth of stromal invasion and nodal involvement. Systemic inflammation score (SIS) is a novel prognostic biomarker which is potential for different types of malignancies. But its role in early stage cervical cancer is unexplored. This study evaluate the impact of SIS on prognostic risk factors for early stage cervical cancer. Methods: This cross sectional study was conducted at Department of Gynecological Oncology, BSMMU, Dhaka, Bangladesh from July 2022 to June 2023. A total of 90 women with IA-IIA clinical stage cervical cancer are included in this study. SIS was categorized into 3 categories (0, 1, 2) and calculated. Chi-square tests and ANOVA were used to analyze associations between SIS and clinicopathologic parameters. Results: SIS was greatly correlated with adverse prognostic features. In 73.7% of patients tumors were >2 cm in patients with SIS 2 compared to 54.5% with SIS 1 and 18.4% with SIS 0 (p<0.001). SIS 2 was present in 92.3% of patients with positive LVSI and in 7.7% (p=0.006) of patients with SIS 0. Higher SIS levels were also associated with increased deepth of stromal invasion and pelvic lymph node metastases. Conclusion: SIS is associated with adverse prognostic factors in early stage cervical cancer. These results may help improve personalized treatment and outcomes through incorporation of SIS into risk assessment models.
Abstract: Background: Cervical cancer is the fourth most common malignancy in women across the world. Treatment decisions for early cervical cancer are guided by prognostic risk factors including tumor size, LVSI, depth of stromal invasion and nodal involvement. Systemic inflammation score (SIS) is a novel prognostic biomarker which is potential for differen...
Show More
,
Sadia Jabeen Khan
